Back to Search Start Over

Cardiovascular concentration–effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies

Authors :
Chotsiri, P
Chan, XHS
Capel, RA
Pike, J
Hanboonkunupakarn, B
Lee, SJ
Hanafiah, M
Win, YN
Cremer, MA
Kiechel, J
Ogutu, B
Taylor, WRJ
Burton, RB
Tarning, J
White, NJ
Source :
British Journal of Clinical Pharmacology. 89:1176-1186
Publication Year :
2022
Publisher :
Wiley, 2022.

Abstract

Aims:Amodiaquine is a 4-aminoquinoline used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Amodiaquine can cause bradycardia, hypotension, and electrocardiograph QT interval prolongation, but the relationship of these changes to drug concentrations is not well characterized. Methods:We conducted a secondary analysis of a pharmacokinetic study of the cardiac safety of amodiaquine (10mg base/kg/day over 3days) in 54 Kenyan adults (≥18 years) with uncomplicated malaria. Nonlinear mixed effects modelling was used to assess amodiaquine and desethylamodiaquine concentration–effect relationships for vital sign (pulse rate, blood pressure) and electrocardiograph interval (QT, QRS, PR) outcomes. We also measured the spontaneous beating heart rate after cumulative dosing of amodiaquine and desethylamodiaquine in isolated mouse atrial preparations. Results:Amodiaquine and desethylamodiaquine caused concentration-dependent mean decreases in pulse rate (1.9 beats/min per 100 nmol/L; 95% confidence interval: 1.5–2.4), supine systolic blood pressure (1.7mmHg per 100 nmol/L; 1.2–2.1), erect systolic blood pressure (1.5mmHg per 100 nmol/L; 1.0–2.0) and erect diastolic blood pressure (1.4mmHg per 100 nmol/L; 1.0–1.7). The mean QT interval prolongation was 1.4 ms per 100 nmol/L irrespective of correction factor after adjustment for residual heart rate dependency. There was no significant effect of drug concentration on postural change in blood pressure or PR and QRS intervals. In mouse atria, the spontaneous beating rate was significantly reduced by amodiaquine (n= 6) and desethylamodiaquine (n= 8) at 3μmol/L (amodiaquine: 10±2%; desethylamodiaquine: 12 ±3%) and 10μmol/L (amodiaquine: 50 ±7%; desethylamodiaquine: 46 ±6%) concentrations with no significant difference in potency between the 2 compounds. Conclusion:Amodiaquine and desethylamodiaquine have concentration-dependent effects on heart rate, blood pressure, and ventricular repolarization.

Details

ISSN :
13652125 and 03065251
Volume :
89
Database :
OpenAIRE
Journal :
British Journal of Clinical Pharmacology
Accession number :
edsair.doi.dedup.....fb7da681d5370dd617eb9a806bbeb23e
Full Text :
https://doi.org/10.1111/bcp.15569